...
首页> 外文期刊>Circulation journal >Therapeutic Effects of Serelaxin in Acute Heart Failure – Necessity for Bilateral Research Translation –
【24h】

Therapeutic Effects of Serelaxin in Acute Heart Failure – Necessity for Bilateral Research Translation –

机译:Serelaxin对急性心力衰竭的治疗作用–双边研究翻译的必要性–

获取原文
           

摘要

Over the past few decades, research on the peptide hormone, relaxin, has significantly improved our understanding of its biological actions under physiological and diseased conditions. This has facilitated the conducting of clinical trials to explore the use of serelaxin (human recombinant relaxin). Acute heart failure (AHF) is a very difficult to treat clinical entity, with limited success so far in developing new drugs to combat it. A recent phase-III RELAX-AHF trial using serelaxin therapy given during hospitalization revealed acute (ameliorated dyspnea) and chronic (improved 180-day survival) effects. Although these findings support a substantial improvement by serelaxin therapy over currently available therapies for AHF, they also raise key questions and stimulate new hypotheses. To facilitate the development of serelaxin as a new drug for heart disease, joint efforts of clinicians, research scientists and pharmacological industries are necessary to study these questions and hypotheses. In this review, after providing a brief summary of clinical findings and the pathophysiology of AHF, we present a working hypothesis of the mechanisms responsible for the observed efficacy of serelaxin in AHF patients. The existing clinical and preclinical data supporting our hypotheses are summarized and discussed. The development of serelaxin as a drug provides an excellent example of the bilateral nature of translational research.??( Circ J ?2014; 78: 542–552)
机译:在过去的几十年中,对肽激素松弛素的研究大大改善了我们对在生理和疾病条件下其生物学作用的理解。这促进了进行临床试验以探索使用serelaxin(人重组松弛素)的方法。急性心力衰竭(AHF)是很难治疗的临床个体,迄今为止在开发新的抗心衰药物方面取得的成功有限。最近一项在住院期间使用serelaxin治疗的III期RELAX-AHF试验显示了急性(缓解的呼吸困难)和慢性(改善的180天生存期)效果。尽管这些发现支持serelaxin疗法比目前可用的AHF疗法有了实质性的改善,但它们也提出了关键问题并激发了新的假设。为了促进Serelaxin作为心脏病新药的发展,临床医生,研究科学家和药理学界需要共同努力研究这些问题和假设。在这篇综述中,在对AHF的临床发现和病理生理学进行了简要总结之后,我们提出了一种机制的工作假设,该机制负责对Serelaxin在AHF患者中观察到的疗效负责。总结和讨论了支持我们假设的现有临床和临床前数据。 serelaxin作为药物的开发为转化研究的双边性质提供了一个很好的例子。(Circ J?2014; 78:542–552)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号